Region: Canada

Examining the practice of Cedar Lane Technologies – America’s top-filing NPE

We talked with Greg Benoit, president of the Canadian company that filed the most cases in 2022, strongly favours the Western District of Texas, and has obtained a 96% settlement rate among its terminated cases

20 March 2023

Second buyer emerges in bid for BlackBerry’s 38,000 patents

New contender is a large firm that does not need external financing but original buyer Catapult IP Innovations is now in final negotiations with new financial partners

21 December 2022

Global tracker: trade secret law

Featured in Special Report 2022 Q4: Trade secret strategy playbook

16 November 2022

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

10 November 2022

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

04 November 2022

BlackBerry has ‘lost the signal’ … again

The series of missteps and errors in the Canadian company’s struggling patent portfolio sale offers a cautionary tale to any IP owner emulating this in future

29 October 2022

Drug royalty sales supercharged by sinking biotech valuations, says leading dealmaker

Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market

03 October 2022

Importance of cash-only agreements plummets in IP licensing, according to new LES USA and Canada report

With the effects of the America Invents Act and Supreme Court eligibility decisions biting, the survey finds that deal values are down overall - with NPEs seeing among the sharpest falls

27 September 2022

$600 million BlackBerry patent deal still alive despite exit of key financial backer

Third Eye Capital syndicate due to provide $400 million for the purchase of the portfolio pulls out, but replacements are said to be on hand

31 August 2022

No decision on possible WiLAN sale yet taken, says Quarterhill CEO

A strategic review that began in December 2021 is ongoing with several options being explored and meanwhile the firm continues to do deals

11 August 2022